B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on BioLife Solutions (NASDAQ:BLFS) on Tuesday, setting a price target of $61, which is approximately 46.60% above the present share price of $41.61.
Mamtani expects BioLife Solutions to post earnings per share (EPS) of $0.20 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in BioLife Solutions, with an average price target of $62.
The analysts price targets range from a high of $65 to a low of $60.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $31.2 million and a net profit of -$2.57 million. The company's market cap is $1.72 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.2% and a 42.65% success rate.
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.